TUESDAY, 1 JuLY
Program subject to change.
| 8:30 - 9:25 | Workshops |
| Workshop 1 - KSCPT and EACPT Workshop 1: Model-informed precision dosing in pediatrics – Focus on cytotoxic agents (Small Hall) Chairs: In-Jin Jang, Seoul National University Hospital, Seoul, Korea and Marja-Liisa Dahl, Karolinska Institute, Stockholm, Sweden | ||
| 8:30 - 8:45 | The long journey to develop Model-Informed Precision Dosing of Busulfan in Korean pediatric patients SeungHwan Lee, Seoul National University Hospital, Seoul, Korea | |
| 8:50 - 9:05 | Multi-center Studies on Busulfan Precision Dosing in Pediatric Patients Eline Muilwijk, Prinses Máxima Centrum, Utrecht, The Netherlands | |
| 9:10 - 9:25 | Carboplatin TDM in childhood cancer patients Gareth Veal, Newcastle University, Newcastle upon Tyne, United Kingdom | |
| EUFEMED Workshop 2: Is there a need for more diversity in clinical drug development: Focus on early clinical trials. (Great Hall) Chairs: Jan de Hoon, University & University Hospitals of Leuven, Leuven, Belgium | ||||||
| 8:30 - 8:45 | The importance of diversity in global drug development: an overview Yves Donazzolo, Eurofins, Lyon, France | |||||
| 8:45 - 9:05 | Diversity in First-in-Human clinical trials: did the healthy volunteer evolve over the last 10 years? Thomas Lodeweyckx, SGS, Antwerp, Belgium | |||||
| 9:05 - 9:25 | Diversity in early-phase clinical trials: when to include patients? Jan de Hoon, University & University Hospitals of Leuven, Leuven, Belgium | |||||
| "Meet the Editors" Workshop 3 (Auditorium) Chairs: Annikka Kalliokoski, Duodecim Medical Publications Ltd, Helsinki, Finland and Thomas Griesbacher, Medical University of Graz, Graz, Austria | ||||||
| 8:30 - 9:25 | Presenters/Panelists Ulf Simonsen, Editor-in-Chief, Basic & Clinical Pharmacology & Toxicology Ann Daly, Senior Editor, British Journal of Clinical Pharmacology Piet van der Graaf, Editor-in-Chief, Clinical Pharmacology & Therapeutics Uwe Fuhr, Managing Editor, European Journal of Clinical Pharmacology | |||||
| 9:30 - 11:00 | Concurrent Sessions | ||||||
| Session A6: Pharmacoeconomics: economic aspects of pharmacotherapy (Small Hall) Chairs: Miia Turpeinen, University of Oulu, Oulu, Finland and Dinko Vitezic, University of Rijeka, Rijeka, Croatia | ||||||
| 9:30 - 10:00 | Health Technology Assessment (HTA): Decisions on treatment efficiency guided by clinical judgement and pharmacoeconomics David Webb, University of Edinburgh, Edinburgh, United Kingdom | ||||
| 10:00 - 10:30 | Innovative cost-sharing models Zoltan Kalo, Semmelweis University, Budapest, Hungary | ||||
| 10:30 - 10:45 | Pharmacoeconomic evidence for disease-modifying therapies in spinal muscular atrophy: experience from systematic and real-world data analyses (Abstract O036) Andrej Belančić, Clinical Hospital Centre Rijeka & University of Rijeka, Faculty of Medicine, Rijeka, Croatia | ||||
| 10:45 - 11:00 | Deprescribing of high dose proton pump inhibitors (PPI’s) in an acute medical unit at NHS University Hospitals of Liverpool Group (Abstract O037) Rebecca Kuruvilla, NHS University Hospitals of Liverpool Group, Liverpool, United Kingdom | ||||
| Session B8: Using routinely collected data to inform clinical pharmacology (Auditorium) Chairs: Aleksi Tornio, University of Turku, Turku, Finland and Caridad Pontes, Universitat Autónoma de Barcelona, Barcelona, Spain | |||||
| 9:30 - 10:00 | Advances in pharmacoepidemiological analyses of real-world data Daniel Prieto-Alhambra, University of Oxford, Oxford, United Kingdom | ||||
| 10:00 - 10:30 | Strategic view on utilizing real-world data during drug development Susana Perez-Gutthann, RTI Health Solutions, Barcelona, Catalonia, Spain | ||||
| 10:30 - 10:45 | Pseudo-worsening of renal function due to inhibition of renal creatinine secretion by oral antitumor therapeutics – a real-world data analysis (Abstract O038) Michael I. Sponfeldner, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany | ||||
| 10:45 - 11:00 | Using pharmacovigilance data for signal detection of breast cancer resistance protein-mediated drug interactions (Abstract O039) Ronja Levomäki, Åbo Akademi University, Turku, Finland | ||||
| Session C7: Global infectious disease threats (Great Hall) Chairs: Asko Järvinen, Helsinki University Hospital, Helsinki, Finland and Markus Zeitlinger, Medical University of Vienna, Vienna, Austria | |||||
| 9:30 - 10:00 | New drugs against multi-drug resistant (MDR) gram negative bacteria - are we loosing the battle against the silent pandemia Günther Weiss, Medical University of Innsbruck, Innsbruck, Austria | ||||
| 10:00 - 10:30 | New vaccine technologies as a response to Covid-19 and other infectious threats Hanna Nohynek, Chair, Strategic Advisory Group of Experts on Immunization (SAGE),WHO, Finland | ||||
| 10:30 - 10:45 | Association of vancomycin pharmacokinetic/pharmacodynamic parameters with clinical outcomes in patients with enterococcal bacteremia: a cohort study (Abstract O040) Eda Kübra Sel, Dokuz Eylul University Faculty of Medicine Department of Medical Pharmacology, İzmir, Türkiye | ||||
| 10:45 - 11:00 | Genome-wide association study on inflammatory neuropathies and SARS-CoV2 vaccines (Abstract O041) Ilma Bertulyte, Department Of Medical Sciences, Clinical Pharmacology, Uppsala University, Uppsala, Sweden | ||||
| 11:00 - 11:20 | Refreshment Break (Catering areas on 1st and 2nd floor) | |||||
| 11:20 - 12:00 | Keynote Lecture 3 (Great Hall) | |||||
| Chair: Gerard Rongen, University of Nijmegen, Nijmegen, the Netherlands No time to lose: From virus hunting to health politics Peter Piot, London School of Hygiene & Tropical Medicine, London, United Kingdom | |||||
12:00 - 13:30 | Lunch and Poster ViewingLunch (Catering areas in 1st and 2nd floor) 12:30 - 13:30 Presenters at posters P246-P270, P358-P391, P430-P446 | |||||
| 13:30 - 15:00 | Concurrent Sessions | |||||
| ESPT & IUPHAR Session A7: Pharmacogenomics - challenges for implementation in different medical specialties (Great Hall) Chairs: Andrew Somogyi, University of Adelaide, Australia and Ann Daly, University of Newcastle, Newcastle, United Kingdom | |||||
| 13:30 - 14:00 | Implementing pharmacogenomics in psychiatry Elvira Bramon, University College London, London, United Kingdom | ||||
| 14:00 - 14:30 | Implementing pharmacogenomics in oncology Matthias Schwab, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany | ||||
| 14:30 - 14:45 | Description of the prevalence of actionable pharmacogenetic variants in the Montreal Heart Institute Hospital Cohort (Abstract O042) Marc-Olivier Pilon, Université de Montréal, Montréal, Canada | ||||
| 14:45 - 15:00 | Pharmacogenetics of repaglinide, gemfibrozil, and their interaction: effects of SLCO1 and CYP2C8 variants (Abstract O043) Anssi Mykkänen, University Of Helsinki, Helsinki, Finland | ||||
| Session B9: Advances in clinical trials methodology (Small Hall) Chairs: Maija Kaukonen, Medbase, Turku, Finland and Florian Naudet, University of Rennes, Rennes, France | |||||
| 13:30 - 14:00 | Routinely collected data (previously named as Real-World Evidence, RWE) integration in clinical trials Lars G. Hemkens, University of Basel, Basel, Switzerland | ||||
| 14:00 - 14:30 | Innovative trial designs: Adaptive and platform trials Mireille Muller, Novartis, Basel, Switzerland | ||||
| 14:30 - 14:45 | Personalized n-of-1 trials for statin intolerance (Abstract O044) Michael Andersen, Department of Clinical Pharmacology, Copenhagen University Hospital - Bispebjerg, Copenhagen, Denmark | ||||
| 14:45 - 15:00 | Pharmacokinetics and pharmacodynamics of AZD7798, a depleting antibody targeting CCR9 +T cells in healthy participants and patients with Crohn’s disease (Abstract O045) Anna Lundahl, Astrazeneca, Gothenburg, Sweden | ||||
| Session C8: New strategies in treatment of cancer (Auditorium) Chairs: Olli Tenhunen, Finnish Medicines Agency Fimea and Oulu University Hospital, Oulu, Finland and Troels K. Bergmann, University of Southern Denmark, Odense, Denmark | |||||
| 13:30 - 14:00 | Repurposing of anti-cancer medicines Kimmo Porkka, University of Helsinki, Helsinki, Finland | ||||
| 14:00 - 14:30 | Patient reported outcomes in cancer drug development Sigrid Klaar, NDA Group - SSI Strategy, Uppsala, Sweden | ||||
| 14:30 - 14:45 | Impact of thiazide and fluoropyrimidine interaction on myelotoxicity and other adverse events: a retrospective cohort study (Abstract O047) Gerard Ronda Roca, University Hospital Puerta de Hierro Majadahonda, Majadahonda (Madrid), Spain | ||||
| 15:00 - 16:00 | Closing Session and Farewells (Great Hall) | |||||
| Awards and closing ceremony Chairs: EACPT Chairperson Janne Backman, University of Helsinki, Helsinki, Finland, and EACPT Past-Chair Gerard Rongen, University of Nijmegen, Nijmegen, the Netherlands Announcement of the 2025 EACPT Scientific Award, followed by the awardee's presentation Poster/Abstract presentation awards Greetings from EACPT Future Congresses Closing words by the EACPT2025 Chairs | |||||